Leukapheresis Market worth $100 million by 2028
The Global Leukapheresis Products Market was estimated to be worth USD 70 million in 2023 and is poised to reach USD 100 million by 2028, growing at a CAGR of 8.3%. The global leukopaks market was estimated to be worth USD 200 million in 2023 and is poised to reach USD 1020 million by 2028, growing at a CAGR of 38.1%.
One of the key trends in the leukopaks market is the increasing use of leukopaks in CAR T-cell therapy. CAR T-cell therapy is a type of immunotherapy that uses the patient's own immune cells to fight cancer. It is a promising new treatment for leukemia and other blood cancers. Leukopaks are used to collect the patient's immune cells, which are then modified to fight cancer. Other trends in the leukopaks market include the increasing demand for leukopaks in personalized medicine and the development of new leukopak collection and storage methods.
Attractive Opportunities in the Leukapheresis Products Market
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=20283148
Leukapheresis Market Dynamics
Drivers: Increased demand for leukopaks in clinical research
Leukopaks are enriched leukapheresis products collected from peripheral blood and consist of various blood cells, including lymphocytes, monocytes, and dendritic cells. Leukopaks are a good source of a variety of immune cells. The need for human cells in any kind of research in the fields of oncology, immunotherapy, or cell biology is the key factor supporting the demand for leukopaks.
Restraints: Complications associated with therapeutic leukapheresis
Therapeutic leukapheresis is associated with certain complications, such as those arising from a decreased WBC count and the possibility of adverse interactions with anticoagulation solutions. Moreover, there may be discomfort, pain, redness, and bruising at the venipuncture site. The procedure may also cause patients to feel dizzy for a short duration and cause loss of consciousness.
Opportunities: Gaps in current leukapheresis technologies
The gaps in current technologies are primarily linked to incomplete or non-cost-effective removal or separation efficiency of bio-products, potential side effects to patients and damage induced to cells during the extraction processes. According to a 2021 study published in the Royal Society of Chemistry, further research needs to take place on interfacial chemistries between the blood and the membrane materials it interacts with.
Challenges: Blood transfusion safety in developing countries
Blood transfusion is a life-saving medical procedure that involves the transfer of blood or blood products from a healthy donor to a recipient. It is used to treat a variety of medical conditions, including anemia, hemorrhage, and cancer. The risk of transfusion-transmitted infections (TTIs) is high in developing countries. TTIs are infections that can be transmitted through blood transfusion. Some of the most common TTIs include HIV, hepatitis B, and hepatitis C. The leukepheresis market is also a major concern in developing countries. This is due to the high cost of leukapheresis equipment and procedures. In addition, there is often a shortage of qualified personnel to perform leukapheresis.
The leukapheresis devices segment is expected to register the highest CAGR during the forecast period.
The leukapheresis devices segment is projected to grow at the highest CAGR during 2023 to 2028. The growth of the leukapheresis devices market can largely be attributed to the increasing number of therapeutic leukapheresis procedures conducted for the treatment of leukemia, immune-mediated inflammatory diseases, and inflammatory bowel diseases. The increasing adoption of leukapheresis instruments by blood collection centers is another major factor supporting market growth.
Request 10% Customization:
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=20283148
The centrifugal devices segment is expected to register the highest CAGR during the forecast period.
The centrifugal devices segment is projected to grow at a higher CAGR during the forecast period 2023 to 2028. Centrifugal apheresis devices are widely used for leukapheresis, blood collection, automated blood component separation, therapeutic plasma exchange, and erythrocytapheresis. Some of the players offering centrifugal devices are Haemonetics Corporation (US), Nikkiso Co., Ltd. (Japan), MacoPahrma SA (France), Terumo BCT (US) and Fresenius Kabi (Germany).
APAC is estimated to be the fastest-growing regional market for leukapheresis.
In 2022, North America accounted for the largest share of the Leukopaks market. Factors like the developed healthcare system in the US and Canada, the presence of a large number of leukopak manufacturing companies in the region, and the easy accessibility to technologically advanced blood separation devices contribute to the growth of this region. Additionally, in 2022, APAC is estimated to be the fastest-growing regional market for leukapheresis. This growth is driven by factors such as the presence of a large number of pharma & biotech companies and research institutes in China and India and the improving life science research infrastructure in several Asia Pacific countries contribute to the growth of this region.
Key Market Players
Key players in the leukapheresis products market include Asahi Kasei Corporation (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Macopharma SA (France), and Miltenyi Biotec (Germany).
Some prominent players in the leukopaks market are Discovery Life Sciences (US), StemExpress, LLC (US), Charles River Laboratories International, Inc. (US), Caltag Medsystems Limited (UK), Lonza Group AG (Switzerland), and ZenBio (US). These companies adopted strategies such as service launches, business expansions, agreements, partnerships, and acquisitions to strengthen their presence in the Leukapheresis market.
Recent Developments
- In May 2022, Fresenius Kabi (Germany) acquired Ivenix, Inc. (US). This acquisition adds a next-generation infusion therapy platform for the significant US market to Fresenius Kabi’s portfolio and provides the company with key capabilities in hospital connectivity.
- In March 2022, Charles River Laboratories International Inc. (US) acquired Retrogenix Limited (UK) to enhance the company’s scientific expertise with additional large molecule and cell therapy discovery capabilities.
- In November 2021, Discovery Life Sciences (US) announced the launch of the Discovery BIOstore, which provides real-time access to Discovery’s inventory of millions of human biospecimens to scientists
Report Link: ( Leukapheresis Market & Leukopaks Market )
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: 1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/leukapheresis-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/leukapheresis.asp
https://finance.yahoo.com/news/leukapheresis-market-worth-100-million-144500254.html
Comments
Post a Comment